Kyowa Kirin’s Ziftomenib Therapy Shows Promise Amid Stock Volatility
Kyowa Kirin’s Ziftomenib combination therapy has shown promising results, potentially driving growth in the company’s pipeline and impacting its stock price.
2 minutes to read
Kyowa Kirin’s Stock Volatility Amid Promising Clinical Data for Ziftomenib
Kyowa Kirin’s stock price has seen significant volatility, but promising clinical data for its investigational menin inhibitor, ziftomenib, is expected to boost investor confidence.
2 minutes to read
Kyowa Kirin Co Ltd: Steadfast Amid Market Volatility with Strong Pharmaceutical Portfolio
Kyowa Kirin Co Ltd has demonstrated remarkable resilience in turbulent markets, driven by its diversified portfolio and commitment to innovation, positioning it as a leader in the Japanese pharmaceutical industry.
2 minutes to read
Kyowa Kirin Expands with $118M Biologics Plant, Boosts Market Presence
Kyowa Kirin Co Ltd is a Japanese pharmaceutical powerhouse on the rise, driven by strategic investments, cutting-edge research, and innovative treatments that are expected to drive growth and strengthen its market position.
2 minutes to read
Kyowa Kirin and Amgen Achieve Breakthrough with Positive ROCKET Phase 3 Results for Atopic Dermatitis Treatment
Kyowa Kirin and Amgen announce positive results from the ROCKET Phase 3 clinical trial program for rocatinlimab, a promising therapy for moderate to severe atopic dermatitis.
2 minutes to read
Kyowa Kirin and Kura Oncology Announce Partnership and Upcoming Milestones in Oncology Research
Kyowa Kirin Co Ltd has announced updates on its partnership with Kura Oncology, including upcoming presentations and submissions for rocatinlimab, a therapy targeting the OX40 receptor.
One minute to read